The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.
about
Tegaserod for constipation-predominant irritable bowel syndrome.Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicineGuidelines on the irritable bowel syndrome: mechanisms and practical management.Novel therapeutic approaches in IBS.The novel, potent and highly selective 5-HT4 receptor agonist YH12852 significantly improves both upper and lower gastrointestinal motility.Pathological Conditions Associated with the Disturbance of the 5-HT System
P2860
The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
The rationale, efficacy and sa ...... t of irritable bowel syndrome.
@ast
The rationale, efficacy and sa ...... t of irritable bowel syndrome.
@en
type
label
The rationale, efficacy and sa ...... t of irritable bowel syndrome.
@ast
The rationale, efficacy and sa ...... t of irritable bowel syndrome.
@en
prefLabel
The rationale, efficacy and sa ...... t of irritable bowel syndrome.
@ast
The rationale, efficacy and sa ...... t of irritable bowel syndrome.
@en
P2860
P356
P1476
The rationale, efficacy and sa ...... nt of irritable bowel syndrome
@en
P2093
Lesley A Houghton
P2860
P304
P356
10.1517/14740338.5.2.313
P407
P577
2006-03-01T00:00:00Z